EUVIMEDEUVIMED entdecken
Crossref

Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center

Yara Maria Machlah iD, Tim Brandenburg iD, Philipp Muchalla, Vera Tiedje, Sarah Theurer, Manuel Weber, Frank Weber, Henning Dralle, Harald Lahner, Dagmar Führer iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Yara Maria Machlah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Protein Kinase Inhibitors, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: University Medicine Essen Clinician Scientist Academy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Multikinase inhibitors (MKIs) have transformed treatment for advanced radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) and medullary thyroid cancer (MTC). However, limited insight exists into management differences between expert centers and multicenter registries or clinical studies. Moreover, MKI efficacy in poorly differentiated thyroid cancer (PDTC) is underreported.

Methods

This retrospective analysis included 154 patients with thyroid cancer (51 PDTC, 49 DTC, 54 MTC) treated with MKIs from 2011 to 2024 at the Essen Endocrine Tumor Center by a consistent specialist team. Clinical characteristics, tumor genetics, time to treatment, and treatment outcomes were assessed. Cox regression analyses identified prognostic survival factors.

Results

In (P)DTC, lenvatinib showed higher objective response rate (ORR) (64% vs 18%) and longer median progression-free survival (PFS) (22.4 vs 6.7 months) than sorafenib, especially in PDTC (21.2 vs 3.5 months). Lenvatinib-treated patients without bone metastases had higher ORR (74% vs 53%), while higher age and liver metastases were associated with shorter PFS (HR, 2.12, P = .039; HR, 2.34, P = .031). In MTC, vandetanib demonstrated higher ORR (60% vs 18%) and longer PFS (26.1 vs 10.0 months) than cabozantinib. Vandetanib as first-line showed higher ORR (67% vs 25%) and RET mutations correlated with longer PFS (HR, 0.14, P = .045).

Conclusion

Lenvatinib outperformed sorafenib, particularly in PDTC, suggesting the need for alternative treatments. In MTC, vandetanib was more effective than cabozantinib, supporting its use as first-line therapy. However, the choice of MKI was determined by the treating physician. Our data highlight MKI effectiveness under expert-center management compared to prior trials and real-world data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsProtein Kinase InhibitorsCarcinoma, NeuroendocrineHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultQuinolinesTertiary Care CentersPhenylurea CompoundsTreatment OutcomeSorafenibPrognosisIodine RadioisotopesAged, 80 and overAnilides

Stichwörter der Autor:innen

DTCMTCPDTCmultikinase inhibitor therapythyroid cancer

Substanzen

lenvatinibProtein Kinase InhibitorsQuinolinesPhenylurea CompoundsSorafenibIodine RadioisotopesAnilides

Autor:innen und Institutionen

  • Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
  • Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN, 45147 Essen, Germany.
  • Department of Medicine and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY 10065, USA.
  • Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
  • Clinic for Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
  • Department of General, Visceral and Transplantation Surgery, Division of Endocrine Surgery, University of Duisburg-Essen, 45147 Essen, Germany.

ORCID-Profile: Yara Maria Machlah, Tim Brandenburg, Dagmar Führer

Förderung

  • University Medicine Essen Clinician Scientist Academy

Zitieren

APA

Machlah, Y. M., Brandenburg, T., Muchalla, P., Tiedje, V., Theurer, S., Weber, M., Weber, F., Dralle, H., Lahner, H., & Führer, D. (2025). Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf286

Vancouver

Machlah YM, Brandenburg T, Muchalla P, Tiedje V, Theurer S, Weber M, et al. Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf286

BibTeX
@article{Machlah2025,
  author = {Machlah, Yara Maria and Brandenburg, Tim and Muchalla, Philipp and Tiedje, Vera and Theurer, Sarah and Weber, Manuel and Weber, Frank and Dralle, Henning and Lahner, Harald and Führer, Dagmar},
  title = {Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf286}
}
Kostenlos starten →